{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:25:40Z","timestamp":1790857540105,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T00:00:00Z","timestamp":1483920000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s40262-016-0502-4","type":"journal-article","created":{"date-parts":[[2017,1,8]],"date-time":"2017-01-08T20:13:00Z","timestamp":1483906380000},"page":"1091-1102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa"],"prefix":"10.1007","volume":"56","author":[{"given":"Ahmed","family":"Nader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Noertersheuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nael","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,9]]},"reference":[{"key":"502_CR1","first-page":"947","volume-title":"Fitzpatrick\u2019s dermatology in general medicine","author":"CC Zouboulis","year":"2012","unstructured":"Zouboulis CC, Tsatsou F. Disorders of the apocrine sweat glands. In: Goldsmith LA, Katz SI, Gilchrest BA, et al., editors. Fitzpatrick\u2019s dermatology in general medicine. 8th ed. New York: McGraw Hill; 2012. p. 947\u201359.","edition":"8"},{"issue":"1","key":"502_CR2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/jid.2012.255","volume":"133","author":"BG Vazquez","year":"2013","unstructured":"Vazquez BG, Alikhan A, Weaver AL, et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013;133(1):97\u2013103.","journal-title":"J Invest Dermatol."},{"key":"502_CR3","doi-asserted-by":"crossref","unstructured":"Jemec GB. Treatment. In: Jemec GB, Revuz J, Leyden J, editors. Hidradenitis suppurativa, Chapter 25. Berlin: Springer; 2006.","DOI":"10.1007\/978-3-540-33101-8_25"},{"issue":"4","key":"502_CR4","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jaad.2009.09.021","volume":"62","author":"\u0141 Matusiak","year":"2010","unstructured":"Matusiak \u0141, Bieniek A, Szepietowski JC. Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol. 2010;62(4):706\u20138.","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"502_CR5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1396-0296.2004.04007.x","volume":"17","author":"MC Wiseman","year":"2004","unstructured":"Wiseman MC. Hidradenitis suppurativa: a review. Dermatol Ther. 2004;17(1):50\u20134.","journal-title":"Dermatol Ther."},{"issue":"4","key":"502_CR6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaad.2008.11.911","volume":"60","author":"A Alikhan","year":"2009","unstructured":"Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60(4):539\u201361 (quiz 562\u20133).","journal-title":"J Am Acad Dermatol."},{"issue":"2","key":"502_CR7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMcp1014163","volume":"366","author":"GBE Jemec","year":"2012","unstructured":"Jemec GBE. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158\u201364.","journal-title":"N Engl J Med."},{"issue":"6","key":"502_CR8","first-page":"730","volume":"137","author":"J Lapins","year":"2001","unstructured":"Lapins J, Weimin Y, Nyren O, et al. Incidence of cancer among patients with hidradenitis suppurativa. Arch Dermatol. 2001;137(6):730\u20134.","journal-title":"Arch Dermatol."},{"issue":"2","key":"502_CR9","doi-asserted-by":"crossref","first-page":"e31810","DOI":"10.1371\/journal.pone.0031810","volume":"7","author":"R Sabat","year":"2012","unstructured":"Sabat R, Chanwangpong A, Schneider-Burrus S, et al. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One. 2012;7(2):e31810.","journal-title":"PLoS One."},{"issue":"2","key":"502_CR10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/jdv.12567","volume":"29","author":"E Shavit","year":"2015","unstructured":"Shavit E, Dreiher J, Freud T, et al. Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2015;29(2):371\u20136.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"4","key":"502_CR11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1046\/j.1365-2133.2001.04137.x","volume":"144","author":"JM Werth von der","year":"2001","unstructured":"von der Werth JM, Jemec GBE. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol. 2001;144(4):809\u201313.","journal-title":"Br J Dermatol."},{"key":"502_CR12","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","volume":"164","author":"HH Zee van der","year":"2011","unstructured":"van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2 and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-\u03b1 and IL-1 \u03b2. Br J Dermatol. 2011;164:1292\u20138.","journal-title":"Br J Dermatol."},{"key":"502_CR13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3109\/09546634.2012.674193","volume":"24","author":"DC Rappard van","year":"2013","unstructured":"van Rappard DC, Limpens J, Mekkes JR. The off-label treatment of severe hidradenitis suppurativa with TNF-alpha inhibitors: a systematic review. J Dermatol Treat. 2013;24:392\u2013404.","journal-title":"J Dermatol Treat."},{"key":"502_CR14","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619\u201344.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"502_CR15","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","volume":"157","author":"AB Kimball","year":"2012","unstructured":"Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157:846\u201355.","journal-title":"Ann Intern Med."},{"key":"502_CR16","doi-asserted-by":"crossref","unstructured":"Kimball AB, Okun MM, Williams DA, et al. Adalimumab in hidradenitis suppurativa: results from two phase 3 trials. New Engl J Med. (In Press).","DOI":"10.1056\/NEJMoa1504370"},{"issue":"6","key":"502_CR17","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/jdv.13216","volume":"30","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (hidradenitis suppurativa clinical response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30(6):989\u201394.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"4","key":"502_CR18","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/MIB.0000000000000327","volume":"21","author":"S Sharma","year":"2015","unstructured":"Sharma S, Eckert D, Hyams JS, et al. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn\u2019s disease: results from a randomized, multicenter, phase-3 study. Inflamm Bowel Dis. 2015;21(4):783\u201392.","journal-title":"Inflamm Bowel Dis."},{"key":"502_CR19","doi-asserted-by":"publisher","unstructured":"Mostafa NM, Nader AM, Noertersheuser P, et al. Impact of immunogenicity on pharmacokinetics, efficacy, and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2016. doi:\n                        10.1111\/jdv.13884\n                        \n                    . (Epub ahead of print).","DOI":"10.1111\/jdv.13884"},{"issue":"2","key":"502_CR20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","volume":"142","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257\u201365.","journal-title":"Gastroenterology."},{"issue":"6","key":"502_CR21","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1097\/MIB.0b013e3182813242","volume":"19","author":"YL Chiu","year":"2013","unstructured":"Chiu YL, Rubin DT, Vermeire S, et al. Serum adalimumab concentration and clinical remission in patients with Crohn\u2019s disease. Inflamm Bowel Dis. 2013;19(6):1112\u201322.","journal-title":"Inflamm Bowel Dis."},{"issue":"12","key":"502_CR22","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1097\/MIB.0000000000000212","volume":"20","author":"I Dotan","year":"2014","unstructured":"Dotan I, Ron Y, Yanai H, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014;20(12):2247\u201359.","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"502_CR23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/0091270008329556","volume":"49","author":"Y Zhu","year":"2009","unstructured":"Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12\/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009;49(2):162\u201375.","journal-title":"J Clin Pharmacol."},{"issue":"9","key":"502_CR24","doi-asserted-by":"crossref","first-page":"596","DOI":"10.5414\/CPP48596","volume":"48","author":"ZH Xu","year":"2010","unstructured":"Xu ZH, Lee H, Vu T, et al. Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity. Int J Clin Pharmacol Ther. 2010;48(9):596\u2013607.","journal-title":"Int J Clin Pharmacol Ther."},{"issue":"1","key":"502_CR25","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106\u201315.","journal-title":"J Am Acad Dermatol."},{"issue":"12","key":"502_CR26","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00228-009-0718-4","volume":"65","author":"AA Fasanmade","year":"2009","unstructured":"Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009;65(12):1211\u201328.","journal-title":"Eur J Clin Pharmacol."},{"issue":"2","key":"502_CR27","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/bcp.12509","volume":"79","author":"D Ternant","year":"2015","unstructured":"Ternant D, Ducourau E, Fuzibet P, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015;79(2):286\u201397.","journal-title":"Br J Clin Pharmacol."},{"issue":"1","key":"502_CR28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cgh.2013.07.010","volume":"12","author":"X Roblin","year":"2014","unstructured":"Roblin X, Marotte H, Rinaudo M, Del Tedesco E, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12(1):80\u20134.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"502_CR29","unstructured":"HUMIRA (adalimumab) [package insert]. North Chicago: AbbVie Inc.; 2015. \n                        http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125057s394lbl.pdf\n                        \n                    . Accessed 7 Dec 2015."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-016-0502-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0502-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0502-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,19]],"date-time":"2017-08-19T02:34:45Z","timestamp":1503110085000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-016-0502-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["502"],"URL":"https:\/\/doi.org\/10.1007\/s40262-016-0502-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,9]]}}}